Recently, the innovative pharmaceutical industry has garnered sustained attention in the capital markets, driven by multiple tailwinds such as policy support, industrial upgrades, and a rebound in sector sentiment. In July 2025, the industry welcomed a new wave of growth opportunities, with market enthusiasm continuing to rise and investor interest in innovative pharmaceuticals increasing significantly.

The Yinhua CSI Innovative Pharma Industry ETF联接C (012782), a representative product that closely tracks the CSI Innovative Pharma Industry Index, has delivered particularly outstanding performance. Over the past month, the fund’s net value growth rate reached 8.94%, outperforming major broad-based indices such as the Shanghai Composite Index and the Shenzhen Component Index. Over the past year, its net value growth rate soared to 40.58%, fully demonstrating the high-growth potential of the innovative pharmaceutical sector in the current market environment.

First, the innovative pharmaceutical industry is at a critical stage of transformation and upgrading. With continuous breakthroughs in domestic biopharmaceutical technology and growing international recognition, innovative drug companies are enhancing their global competitiveness.

Second, the Yinhua CSI Innovative Pharma Industry ETF联接C has strong capital appeal. According to Wind data, the fund recorded net inflows over the five-day period from August 9 to August 13, 2025, reflecting sustained investor confidence.

The fund also excels in cost control, with a management fee of 0.50% and a custody fee of 0.05%. Its transparent and reasonable fee structure helps reduce holding costs for investors.

Additionally, the fund adopts a passive index-tracking strategy, closely following the CSI Innovative Pharma Industry Index. Its performance benchmark is "95% CSI Innovative Pharma Industry Index Return + 5% After-Tax Bank Demand Deposit Rate," ensuring clear and measurable investment objectives.

Managed by Yinhua Fund Management Co., Ltd., a firm with years of experience in the financial industry and deep expertise in index investing, the fund benefits from strong institutional backing. Its current fund manager, Wang Shuai, who took charge on December 30, 2021, brings extensive experience in managing multiple fund products, ensuring stable operations.

As market interest in the innovative pharmaceutical industry continues to grow, the fund is expected to attract further capital inflows, strengthening its market influence. For investors seeking to capitalize on the sector’s growth opportunities, the Yinhua CSI Innovative Pharma Industry ETF联接C offers a convenient and efficient investment channel.